Company Overview

Inspira Technologies Oxy B.H.N. Ltd. is a medical technology company focused on developing respiratory support technologies for patients with acute respiratory failure. The company operates within the medical devices and critical care industries, with a primary emphasis on extracorporeal oxygenation solutions intended to improve blood oxygen levels without the need for invasive mechanical ventilation. Its core product development centers on the INSPIRA ART™ system, designed to provide oxygenation support while potentially reducing complications associated with traditional ventilation and extracorporeal membrane oxygenation (ECMO).

The company was founded in Israel and later became publicly listed in the United States. Inspira Technologies’ strategy has evolved from early-stage research and development toward pre-commercial validation, regulatory advancement, and clinical testing. The company positions itself as addressing unmet needs in intensive care and emergency medicine, particularly for patients suffering from acute respiratory distress syndrome (ARDS) and other life-threatening pulmonary conditions.

Business Operations

Inspira Technologies operates primarily as a development-stage company, with operations centered on research, engineering, clinical validation, and regulatory preparation. Its principal business activity is the development of proprietary oxygenation technologies, including the INSPIRA ART™ system, which is designed to oxygenate blood using an extracorporeal circuit while avoiding full cardiopulmonary bypass. The company does not currently report material commercial revenue, as its products remain in development and regulatory review stages.

Operational activities are concentrated in product design, laboratory testing, preclinical studies, and preparation for human clinical trials. The company controls proprietary know-how related to oxygenation methods, device architecture, and blood flow management. Manufacturing, commercialization, and large-scale distribution have not yet been established, and available public information indicates no material reliance on joint ventures or revenue-generating subsidiaries at this stage.

Strategic Position & Investments

Strategically, Inspira Technologies is focused on advancing its technology toward regulatory clearance and eventual commercialization in major healthcare markets. Growth initiatives center on clinical trials, regulatory engagement, and further refinement of its oxygenation platform to expand potential indications. The company has publicly stated its intention to position its technology as a bridge or alternative to invasive ventilation and ECMO in critical care settings.

The company’s investments are primarily directed toward internal research and development rather than external acquisitions. No completed material acquisitions or controlling investments in other operating companies have been consistently disclosed across public filings. Inspira Technologies’ strategic emphasis remains on proprietary device development, intellectual property protection, and potential future partnerships with hospitals, research institutions, or medical device manufacturers. Data inconclusive based on available public sources regarding finalized long-term commercial partnerships.

Geographic Footprint

Inspira Technologies is headquartered in Israel, where its primary research and development activities are conducted. The company also maintains a corporate presence in the United States, reflecting its public market listing and strategic focus on U.S. regulatory pathways and healthcare markets. These two regions represent the company’s principal geographic footprint.

While the company’s technology is intended for global application in critical care environments, there is no verified evidence of active commercial operations or sales across Europe, Asia-Pacific, or other regions as of the most recent public disclosures. International influence at this stage is primarily limited to regulatory planning, investor engagement, and prospective future market entry rather than established operational infrastructure.

Leadership & Governance

Inspira Technologies was founded by medical and technology professionals with experience in biomedical innovation and device development. The leadership team emphasizes innovation in life-support technologies and a long-term vision of improving outcomes for critically ill patients through less invasive solutions. Governance follows a standard public-company structure with executive management oversight and a board of directors.

Key executives include:

• Dagi Ben-Noon – Chief Executive Officer
• Ariel Meirovich – President and Director
• Ilan Rachmilevitz – Chief Financial Officer
• Yehuda Karmon – Chief Technology Officer

The leadership philosophy centers on clinical impact, regulatory discipline, and technology-driven differentiation. Strategic vision, as described in public disclosures, prioritizes patient safety, evidence-based development, and positioning the company for future partnerships or commercialization opportunities within the global critical care ecosystem.